Divulgação

Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement

marco.marques 2016-10-16T12:02:14+01:00 2012-8-17|Categories: Divulgação|Tags: Raynaud, SSc, UCTD|

Introduction. We investigated early Systemic Sclerosis (SSc) (i.e. Raynaud’s phenomenon with SSc marker autoantibodies and/or typical capillaroscopic findings and no manifestations other than puffy fingers or arthritis) versus Undifferentiated Connective Tissue Disease (UCTD) to identify predictors of short-term disease evolution. Methods. Thirty-nine early SSc and 37 UCTD patients were investigated. At baseline, all patients underwent clinical evaluation, B-mode echocardiography, lung [...]

Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label

marco.marques 2016-10-16T12:02:14+01:00 2011-12-1|Categories: Divulgação|Tags: adalimumab, etanercept, Infection rate, infliximab, rituximab, Sjögren syndrome, systemic lupus erythematosus, vasculitis|

Introduction: The purpose of this observational study was to analyze the rates, characteristics and associated risk factors of severe infections in patients with systemic autoimmune diseases (SAD) who were treated off-label with biological agents in daily practice. Methods: The BIOGEAS registry is an ongoing Spanish prospective cohort study investigating the long-term safety and efficacy of the off-label use of [...]

Intensified COBRA therapy induces remission in 90% of patients with early RA

marco.marques 2016-07-09T08:55:32+01:00 2009-10-27|Categories: Divulgação|

Nature Clinical Practice Rheumatology 4, 564 (2008). Ver artigo completo

Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis

marco.marques 2016-10-16T12:02:18+01:00 2008-12-3|Categories: Divulgação|

Norbert Blank, Regina Max, Martin Schiller, Steffen Briem and Hanns-Martin Lorenz SIR, Treatment of RA with rituximab (RTX) is established for patients with an inadequate response to anti-TNF-α therapy [1–3]. Previous RTX trials show an ACR-70 response in ∼15% of all patients after 24 weeks [2, 3]. Therefore, a significant fraction of RA patients cannot be treated sufficiently. Other trials showed that [...]